Xiaolu Biologics Secures Tens of Millions in USD in Angel Funding to Advance Next-Generation Immunotherapies

VCBeat has learned that recently, Professor Liu Yongjun, a globally renowned immunologist, founded in early 2025Suzhou XIAOLU Biomedicine Co., Ltd. (hereinafter referred to as:XIAOLU Biomedicine）Recently completed an angel round of financing amounting to tens of millions of US dollars. This round of financing was led byYuanBio Venture Capital, Qiji InvestmentLead Investor,Oriza Holdings, Hillhouse Capital, Suzhou Venture Capital Group, Boquan Capital, Beijing Life Science Park, Hefei Industrial Investmentand other institutions co-invested.

XIAOLU Biomedicine focuses on the R&D of innovative drugs for autoimmune and inflammatory diseases, building a first-class R&D team, independent R&D strategies, and a unique antibody technology platform. The company is committed to developing safe and highly effective next-generation drugs by identifying the most fundamental targets and target combinations based on pathogenic mechanisms, thereby creating third-generation drugs with enhanced efficacy and longer duration of action, striving to achieve the goal of being a global first-in-class and internationally leading enterprise.

For this round of financing,Professor Liu Yongjun, Founder of XIAOLU BiomedicineStatement: We extend our sincere gratitude to all investors for their trust and support! This angel round of financing is of significant importance to XIAOLU Biomedicine, providing ample seed capital for the research and development as well as industrialization of our next-generation autoimmune and inflammatory disease therapeutics. Furthermore, it represents a strong endorsement from the capital markets of XIAOLU Biomedicine’s strategic commitment to deep iterative innovation within the autoimmune field.

Chen Jie, Founding Partner of YuanBio Venture CapitalProfessor Liu Yongjun, a world-renowned Chinese scientist, has made monumental contributions to the field of immunology. His pioneering research has charted the course for the development of immunological therapeutics. He has personally spearheaded the clinical advancement of numerous autoimmune drugs with global competitiveness at both multinational pharmaceutical companies and local biotechnology firms, demonstrating exceptional efficacy. As the lead investor in this financing round, we are delighted to serve as a steadfast partner in Professor Liu’s entrepreneurial journey, providing comprehensive support in company registration and establishment, team building, and facility acquisition. In recent years, the achievements of China’s innovative drug sector have been widely recognized, with an increasing number of domestically developed new drugs gaining favor from multinational pharmaceutical companies. We believe that under Professor Liu’s leadership, XIAOLU Biomedicine will develop a portfolio of high-quality, highly innovative new drugs that are closely aligned with clinical needs and possess strong international competitiveness, thereby delivering breakthrough therapies for patients with immune-mediated diseases worldwide.

XIAOLU Biomedicine, founded by the internationally renowned immunologist Professor Liu Yongjun, established its presence in Suzhou Industrial Park’s BioBAY in early 2025. Leveraging Professor Liu’s distinguished scientific expertise and industry experience, XIAOLU Biomedicine transcends the generational limitations of existing autoimmune therapies. The company focuses on developing third-generation therapeutics targeting diseases with significant unmet clinical needs in the fields of autoimmunity and inflammation. By elucidating the heterogeneous pathogenic mechanisms of autoimmune diseases, XIAOLU has constructed a foundational innovation system for precision immunotherapy, achieving a leap from isolated technological breakthroughs to systematic, source-level innovation. Adopting an iterative R&D strategy rooted in the fundamental nature of diseases, the company is accelerating the market launch of globally competitive breakthrough therapies to provide superior solutions for patients.

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector, headquartered in Suzhou BioBAY with a global reach. To date, it has invested in over 200 outstanding companies in the life and health sectors, covering four key areas: innovative drug development, medical devices, in vitro diagnostics and precision medicine, as well as healthcare services. The firm has achieved substantial investment returns, with 20 of its portfolio companies listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. Bringing together seasoned professional investors and a team of world-class scientific advisors, YuanBio Venture Capital possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, the firm is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.